<DOC>
	<DOCNO>NCT00871182</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy inhale PT001 compare placebo tiotropium patient mild moderate chronic obstructive pulmonary disease ( COPD ) .</brief_summary>
	<brief_title>Study Evaluate Safety Efficacy Inhaled PT001 Patients With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Tiotropium Bromide</mesh_term>
	<criteria>Signed write informed consent 40 75 year age Females nonchild bear potential female child bear potential negative pregnancy test ; acceptable contraceptive method COPD diagnosis Current/former smoker least 10 packyear history cigarette smoking Patients establish clinical history COPD severity define postipratropium FEV1/FVC ratio ≤0.70 FEV1 ≥50 ≤85 % predict normal Screening Must demonstrate reversibility ipratropium demonstrate &gt; 200 mL improvement baseline and/or &gt; 12 % &gt; 150 mL improvement baseline Patients willing stay study site least 24 hour test day Women pregnant lactate Primary diagnosis asthma Alpha1 antitrypsin deficiency cause COPD Active pulmonary disease Prior lung volume reduction surgery Abnormal chest Xray ( CT scan ) due presence COPD Hospitalized due poorly control COPD within 24 week Screening Unable perform acceptable spirometry Poorly control COPD prior 6weeks , define occurrence acute worsen COPD require corticosteroid antibiotic acute worsen COPD require treatment prescribe physician Clinically significant medical condition Symptomatic prostatic hypertrophy bladder neck obstruction Known narrowangle glaucoma Lower respiratory tract infection require antibiotic past 6 week Clinically significant abnormal ECG Clinically significant uncontrolled hypertension Positive Hepatitis B surface antigen Hepatitis C antibody Cancer complete remission least 5 year History hypersensitivity beta2agonists anticholinergic History severe milk protein allergy Known suspect history alcohol drug abuse Medically unable withhold short act bronchodilator 6hours Use medication specify time interval prior Screening : 3 month : depot corticosteroid , intraarticular corticosteroid ; 6 week : oral corticosteroid , antibiotic administer COPD exacerbation ; 1 month : Pglycoprotein inhibitor , CYP450 3A4 inhibitor , ICS &gt; 1000 μg/day fluticasone propionate equivalent The following COPD medication need stop switched appropriate replacement therapy : tiotropium , oral beta2 agonist , LABAs , combination corticosteroid/LABAs , theophylline , leukotriene inhibitor , cromoglycate nedocromil Use follow medication prohibit : tricyclic antidepressant , monoamine oxidase ( MAO ) inhibitor , betaadrenergic antagonist , anticonvulsant ( barbiturate , hydantoin , carbamazepine phenothiazine Receiving longtermoxygen nocturnal oxygen therapy &gt; 12 hour day Diagnosis sleep apnea uncontrolled Participation acute phase pulmonary rehabilitation prior 4 week Will enter acute phase pulmonary rehabilitation program study Unable comply study procedure Affiliated Investigator site Questionable validity consent Use investigational study drug/participation clinical study last 30 day 5 half life prior Screening , whichever long</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>COPD</keyword>
	<keyword>obstructive lung disease</keyword>
	<keyword>Tiotropium</keyword>
</DOC>